title: Validation of connective tissue growth factor (CTGF/CCN2) and its gene polymorphisms as noninvasive biomarkers for the assessment of liver fibrosis.
abstract: Clinical and experimental studies have demonstrated that connective-tissue growth factor (CTGF) expression is increased in fibrotic human liver and experimental animal models of liver fibrogenesis. CTGF has been linked to transforming growth factor-beta (TGF-beta) pathways in fibroproliferative diseases and specific polymorphisms within the CTGF gene may predispose for fibrosis in systemic sclerosis. As CTGF is detectable in various human fluids (serum, plasma and urine), it may provide information about fibrotic remodelling processes and reflect hepatic TGF-beta bioactivity. We established a novel ELISA for the measurement of serum CTGF and tested its clinical value in patients with chronic hepatitis C virus (HCV) infection and chronic liver disease (CLD). HCV infected patients (n = 138) had significantly higher serum CTGF levels than healthy controls. CTGF was linked to the histological degree of liver fibrosis. To expand the results to other aetiologies, a separate cohort of CLD patients (n = 129) was evaluated, showing higher serum CTGF than healthy controls and again an association with advanced stages of liver cirrhosis (Child B and C). Although independent of the underlying aetiology, serum CTGF was most powerful in indicating fibrosis/advanced disease states in HCV-related disorders. The genotyping of six polymorphisms (rs6917644, rs9399005, rs6918698, rs9493150, rs2151532 and rs11966728) covering the CTGF locus in 365 patients suffering from chronic hepatitis C revealed that none of these polymorphisms showed a genotypic or allelic association with the severity of hepatic fibrosis. Taken together, serum CTGF is suitable for determination of hepatic fibrosis and most powerful in patients with chronic HCV infection.
authors.affiliation: Institute of Clinical Chemistry and Pathobiochemistry, RWTH-University Hospital, Aachen, Germany.
authors.forename: E
authors.initials: E
authors.lastname: Kovalenko
authors.forename: F
authors.initials: F
authors.lastname: Tacke
authors.forename: O A
authors.initials: OA
authors.lastname: Gressner
authors.forename: H W
authors.initials: HW
authors.lastname: Zimmermann
authors.forename: B
authors.initials: B
authors.lastname: Lahme
authors.forename: A
authors.initials: A
authors.lastname: Janetzko
authors.forename: T
authors.initials: T
authors.lastname: Wiederholt
authors.forename: T
authors.initials: T
authors.lastname: Berg
authors.forename: T
authors.initials: T
authors.lastname: Müller
authors.forename: C
authors.initials: C
authors.lastname: Trautwein
authors.forename: A M
authors.initials: AM
authors.lastname: Gressner
authors.forename: R
authors.initials: R
authors.lastname: Weiskirchen
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D015415:Biomarkers; D055513:Connective Tissue Growth Factor / Q000097:blood* / Q000235:genetics*; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods*; D005260:Female; D005787:Gene Frequency; D005819:Genetic Markers; D006801:Humans; D008103:Liver Cirrhosis / Q000175:diagnosis* / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D011110:Polymorphism, Genetic; D011379:Prognosis; D055815:Young Adult
chemical_list: D015415:Biomarkers; C526317:CCN2 protein, human; D005819:Genetic Markers; D055513:Connective Tissue Growth Factor